How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH
WESTBOROUGH, Mass., Aug. 18, 2025 /PRNewswire/ —Â Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening…